Minimizing Regulatory Risk For Biologics Manufacturing Changes

By Megha Sinha, founder and CEO, Kamet Consulting Group

The biopharma industry has spent decades mastering the science of making biologics. The manufacturing processes are complex, the regulatory expectations are stringent, and the investment required to achieve and maintain approval is substantial. What happens operationally beyond approval has received much less attention. This is when every change to those hard-won manufacturing processes (however well-justified scientifically) must be navigated through a global regulatory system that is fragmented, slow, and almost entirely managed through manual coordination.

Post-approval change management for biologics presents a very different challenge from that of manufacturers of small molecules. Here, it is not typically an issue of volume (a biologic product may be registered in fewer markets than a mature oral solid product), but rather of technical and regulatory complexity per change — and the consequences when this is underestimated.

Any manufacturing process change for a biologic — a site transfer, a scale-up, a change in raw material supplier, a modification to the upstream cell culture process — can raise comparability questions that simply do not arise for chemically synthesized drugs. Health authorities need to be satisfied that the product made after the change is the same product as the one that was approved: the same efficacy profile, the same safety profile, the same quality attributes. Generating that comparability data package takes months. If testing reveals unexpected differences — a shift in glycosylation pattern, a change in aggregation profile, a potency variance outside specification — what began as a standard variation can escalate to a major filing requiring clinical bridging data, adding one to two years to an already lengthy approval timeline in every market where the change must be filed.

While the submission volumes may be lower for biologics manufacturers (a large traditional pharma company could be assessing some 6,000 post-approval changes every year^1,2), the risk per filing is significantly higher, and the cross-functional coordination required to manage a single manufacturing change is considerably more demanding.

A Problem Made Worse By Converging Pressures

The operational burden of biologics post-approval change management is intensifying from several directions simultaneously. The U.S. BIOSECURE Act, now signed into law, is forcing a fundamental reassessment of manufacturing and CDMO relationships, with companies that have historically relied on Chinese CDMOs for biologics production now actively evaluating alternatives. Every supplier or site change for a biologic product triggers a comparability exercise, a regulatory filing strategy, and a multiyear approval process in each market. Companies making these transitions reactively, without a structured view of the regulatory implications across their full product portfolio, are creating significant risk exposure.

The biosimilars landscape is simultaneously reshaping the way that innovator biologics companies manage their marketed portfolios. As products approach patent expiry and face biosimilar competition, commercial teams are pushing for cost reductions in the form of manufacturing efficiencies, supplier consolidation, and site rationalization, for example. Each initiative generates post-approval changes, which must be planned, filed, and tracked across multiple jurisdictions. The regulatory operations teams responsible for executing these programs are rarely expanding at the same rate as the change volume they are being asked to absorb.

Regulatory divergence adds a further layer of difficulty specific to biologics. The comparability framework under ICH Q5E is a reference point,³ but its interpretation varies significantly among health authorities. What one agency accepts as a straightforward comparability exercise for a monoclonal antibody (mAb) site transfer, another may treat as requiring a full comparability protocol with an extended analytical data package. In some markets, a manufacturing change approved through a prior approval supplement in the U.S. and a Type II variation in Europe may require a completely separate submission category in Asia-Pacific or Latin American markets. Each of those country-specific requirements must be identified, planned for, and tracked against a supply chain transition that cannot wait indefinitely for the slowest market to catch up.

The Coordination Failure At The Heart Of The Problem

The reason biologics organizations consistently underestimate the operational challenge of post-approval change management is the same reason the industry as a whole has struggled with it. No single function owns the process end to end. The manufacturing science (MSAT) team generates the comparability data; regulatory affairs manages the submission strategy; supply chain plans the transition; quality owns change control; and commercial sets the deadline. In most organizations, these workstreams operate in parallel but with limited shared visibility. The gaps between them are where the most costly failures tend to occur.

I have witnessed a large-scale biologics site transfer where the comparability data package was delayed by three months due to unexpected analytical results. The supply chain team had already committed to the new site cutover date based on the original approval timeline. The regulatory team’s revised timeline was not reflected in the supply plan until two weeks before the cutover, at which point it was too late to rebuild buffer stock at the old site. The result was a supply gap in several markets, with revenue at risk in the millions and an expedited shipment program that cost far more than the delay itself.

In a separate case involving a marketing authorization holder (MAH) transfer across more than 80 countries following a divestiture, the absence of a unified view of country-level requirements led to inconsistent filings across jurisdictions — with some markets receiving Type II variation submissions and others receiving notifications for the same underlying change. The regulatory remediation program that followed took over two years and cost several million dollars to resolve. This would have been entirely avoidable with up-front planning.

Actionable Priorities For Biologics Organizations

For CMC heads, regulatory affairs leaders, and COOs managing biologics portfolios, there are three areas where investment delivers the most immediate return:

1. Build a structured regulatory intelligence layer for post-approval changes specific to biologics. Generic regulatory databases capture submission categories and review timelines, but they rarely encode the operational detail that matters: which markets require a comparability protocol as a condition of prior approval submission, which health authorities have a history of raising analytical questions on mAb site transfers, which markets have no implementation grace period. That knowledge exists within experienced teams but is not systematically captured. Building a validated repository of this intelligence — one that can be applied automatically to every change in the planning process — reduces the risk of costly surprises in execution.
2. Integrate comparability planning into the change initiation process, not just the submission preparation process. The comparability data package for a biologics manufacturing change is almost always the gating item for the regulatory timeline and therefore for the supply chain transition. The earlier that comparability risk is assessed — at the point when a change is being considered, not after it has been approved internally — the more time the team has to design around it, engage health authorities proactively, and plan supply transitions that reflect the realistic regulatory timeline rather than an optimistic one.
3. Create genuine cross-functional visibility. The manufacturing science team, regulatory affairs, supply chain, and quality need to be operating from a single version of the program plan, with shared milestones, shared risk flags, and shared visibility into how a delay in one workstream affects all the others. The AI tools now available can encode the regulatory intelligence, compute the cross-functional dependencies, and surface the risks before they become supply gaps. From a practical standpoint, the opportunity for AI to deliver real operational return in biologics life cycle change management is significantly higher than in most other areas currently attracting investment in this space.

The biologics industry has invested enormous effort in understanding how to make these products. It now needs to invest equivalent effort in understanding how to change them — consistently, predictably, and without putting supply to patients at risk.

References:

1. Harris R. et al., “An Evaluation of Postapproval CMC Change Timelines,” ISPE’s Pharmaceutical Engineering journal, September/October 2023. Available at: https://ispe.org/pharmaceutical-engineering/september-october-2023/evaluation-postapproval-cmc-change-timelines
2. Vinther A. et al., “Approaches to Design an Efficient, Predictable Global Post-approval Change Management System,” Therapeutic Innovation & Regulatory Science, 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11043098/
3. The ICH Q5E guideline provides a scientific, risk-based framework for evaluating the comparability of biotechnological/biological products before and after manufacturing process changes. EMA guideline: https://www.ema.europa.eu/en/ich-q5e-biotechnological-biological-products-subject-changes-their-manufacturing-process-comparability-biotechnological-biological-products-scientific-guideline

About The Author:

Megha Sinha is founder and CEO of Kamet Consulting Group, which advises global pharmaceutical and life sciences companies on regulatory operations, quality, and large-scale transformation. With more than 17 years’ experience across the industry, including senior leadership roles at global consulting firm PwC, Sinha has worked with many of the world’s largest pharma organizations, solving their most complex regulatory, supply chain, and life cycle management challenges.